- National laboratory cancels ‘Southern Accent Reduction’ classes after outcry
- U.S. woman with Ebola is stable, improving, son says
- Belgium pushes for clear labeling of goods from Israeli settlements
- ‘Queen of Mean’ Leona Helmsley’s former home hits market for $65M
- Florida beach-goers told to beware flesh-eating bacteria in water
- Lundergan Grimes uses ‘war on women’ strategy to attack McConnell
- Rep. Jeff Miller: ‘Ain’t no leash for VA’
- Al Qaeda nets $125M from ransom payoffs from Europe since 2008
- Ohio Gov. John Kasich cruising to re-election: survey
- Landslide hits Indian village; 150 may be trapped
FDA expands approval of J&J prostate cancer drug
Question of the Day
WASHINGTON (AP) - The Food and Drug Administration on Monday expanded approval of Johnson & Johnson’s prostate cancer pill Zytiga for men with an earlier stage of the disease.
The agency says Zytiga is now approved for late-stage prostate cancer patients who have not yet received chemotherapy, based on study results showing it can extend life by up to five months when taken by men in that group.
The FDA previously approved the drug in April 2011 for men with prostate cancer who have already taken the chemotherapy drug docetaxel.
Zytiga works by decreasing the male hormone testosterone. Testosterone stimulates the growth of prostate tumors, and treatment often includes drugs aimed at cutting the body’s testosterone production. While older drugs can block about 90 percent of the hormone, scientists say Zytiga blocks virtually all of it, which can help slow the disease.
The FDA approved the new indication based on a J&J study of 1,088 men with late-stage prostate cancer who had not already received chemotherapy.
The typical patient taking Zytiga survived five months longer than the typical patient taking a fake pill, or placebo.
When the study was stopped, the median time until cancer worsened in the group getting dummy pills was about eight months. Those on Zytiga were faring much better, so researchers could not yet report how long it would take their cancers to worsen.
FDA cancer drugs chief Dr. Richard Pazdur said the FDA’s approval “provides patients and health care providers the option of using Zytiga earlier in the course of treatment.”
Common side effects with the drug include fatigue, joint swelling, diarrhea, vomiting, cough and shortness of breath.
Shares of Johnson & Johnson rose 10 cents to $70.55 in afternoon trading Monday.
TWT Video Picks
- Patent workers paid to exercise, shop, do chores: report
- Boehner rules out impeachment: 'Scam started by Democrats'
- CARSON: Rudderless U.S. foreign policy
- Obama thanks Muslims for 'building the very fabric of our nation'
- Fla. mom arrested for allowing 7-year-old son to walk to park alone
- Smugglers, rainstorm combine to poke holes in border fence
- Obama mum on where illegal immigrant children are sheltered
- Federal judge grants 90-day stay in D.C. gun case
- Defense lawyer: McDonnell's wife had 'crush' on CEO
- CARSON: Costco and the perils of politicizing business
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world